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Abstract
Background: Distant recurrence is one of the most important risk factors in overall survival, and distant recurrence
is related to a complex biologic interaction of seed and soil factors. The aim of the study was to investigate the
association between the molecular subtypes and patterns of distant recurrence in patients with breast cancer.
Methods: In an investigation of 313 women with breast cancer who underwent surgery from 1994 and 2000, the
expressions of estrogen and progestrone receptor (ER/PR), and human epithelial receptor-2 (HER2) were evaluated.
The subtypes were defined as luminal-A, luminal-HER2, HER2-enriched, and triple negative breast cancer (TNBC)
according to ER, PR, and HER2 status.
Results: Bone was the most common site of distant recurrence. The incidence of first distant recurrence site was
significantly different among the subtypes. Brain metastasis was more frequent in the luminal-HER2 and TNBC
subtypes. In subgroup analysis, overall survival in patients with distant recurrence after 24 months after surgery was
significantly different among the subtypes.
Conclusions: Organ-specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies
against distant metastasis concerning the molecular subtypes in breast cancer may be considered.
Keywords: breast neoplasms, neoplasm metastasis, survival, molecular subtype, estrogen, erbB-2
Background
Distant recurrence of breast cancer results in poor sur-
vival outcome and the site of the distant recurrence is
also important to predict the clinical outcome [1]. The
complex interaction between the primary cancer and
metastatic sites includes tumor intravasation, circulation,
extravasation, proliferation, and angiogenesis, and the
microenvironment of the target tissue, so called “seed
and soil” theory, may be associated with organ-specific
metastasis in cancer patients [2,3].
The advances in the understanding of molecular sub-
types analyzed by hierarchical clustering using an intrin-
sic gene list have identified molecular subtypes of breast
cancer, and it has been noted that there is a significant
difference in survival among the molecular subtypes of
breast cancer [4,5]. The predictive and prognostic fac-
tors including tumor size, nodal status, lymphovascular
invasion, estrogen receptor (ER) or progesterone recep-
tor (PR), and human epithelial receptor 2 (HER2) has
been investigated widely concerning molecular subtypes
[6]. However, data are limited concerning differences in
distant recurrence sites between the breast cancer sub-
types [7]. Thus, the aim of the study was to investigate
whether these subtypes were related to an organ-specific
metastasis.
Methods
Patients
Three hundred thirteen women with primary breast
cancer who underwent surgery at Seoul St. Mary’s Hos-
pital between 1994 and 2000 were enrolled in the study.
Their medical data were retrospectively analyzed. Clini-
copathological features including tumor size; nodal
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status; operation type; expression of ER, PR, and HER2;
lymphovascular invasion; status of systemic therapy
including endocrine or chemotherapy; radiation therapy;
site and date of up to the first three recurrences; and
survival data were reviewed using the medical database
of Seoul St. Mary’s Hospital.
Molecular subtypes
Molecular subtypes of breast cancer were categorized
according to ER, PR, and HER2 status; we defined ER or
PR positive and HER2 negative as luminal-A, ER or PR
positive and HER2 positive as luminal-HER2, ER and PR
negative with HER2 positive as HER2-enriched, and all
negative as triple negative breast cancer (TNBC)
subtype.
Distant recurrence and survival analysis
Distant recurrence was diagnosed by clinical evaluations
including imaging studies or biopsy. Distant recurrence
was defined as a recurrence of breast cancer developing
beyond the ipsilateral or contralateral breast, chest wall,
or regional lymph node including ipsilateral axillary,
supraclavicular, or internal mammary lymph node.
Cumulative frequency of bone (including bone marrow),
lung, pleural or peritoneal, liver, brain, and other sites of
metastasis (including soft tissue, pericardium, ovary,
periampullary area, and other organs not elsewhere
documented) during follow-up was analyzed regarding
to the molecular subtypes. The site of the first distant
recurrence was categorized as follows: bone, extra-bone
metastasis (lung, pleural or peritoneal metastasis, liver,
and other site metastasis) excluding brain metastasis,
bone metastasis with synchronous extra-bone metastasis,
brain metastasis, and brain metastasis with synchronous
bone or extra-bone metastasis. Distant recurrence-free
survival (DRFS) was defined as the time from operation
to the first distant recurrence, and the cases of death
without distant recurrence was censored at the time of
the death. Overall survival (OS) was defined as the time
from operation to death from any cause.
ER, PR and HER2 status
ER and PR status were reviewed by medical records.
Hormone receptor status was determined using an
enzyme immunoassay and reported in the medical
record between 1994 and 2000. The receptor status had
been determined using a commercial enzyme immu-
noassay according to the instructions of the manufac-
turer (Abbott Laboratories, Chicago, IL, USA). A result
exceeding 15 fmol/mg was considered positive for the
presence of the particular receptor. Tissue microarray
(TMA) of primary breast tissue was used for analysis of
HER2 overexpression. Immunohistochemistry (IHC) or
florescence in situ hybridization (FISH) for evaluating
HER2 status was performed, and an IHC score of 3
positive or FISH positive was defined as positive for
HER2 overexpression. The IHC method was briefly
described as follows; Five-micrometer sections of paraf-
fin-embedded tissue arrays were deparaffinized, rehy-
drated in a graded series of alcohol solutions and
microwave-treated for 10 min in a pH 6.0 citrate buffer.
The endogenous peroxidase activity was blocked using
0.3% hydrogen peroxide. The tissue arrays were pro-
cessed in an automatic IHC staining machine using
standard procedures (Lab Vision autostainer; Lab Vision,
Fremont, CA, USA) and a ChemMate™ EnVision™ sys-
tem (DAKO, Carpinteria, CA, USA). FISH was per-
formed using the PathVysion™ HER2/CEN probe
(Vysis, Downers Grove, IL, USA). The c-erbB2 to chro-
mosome 17 centromere ratio was measured in at least
60 nuclei from the tumor cells, and an average score
was taken. More than two copies of c-erbB2 for each
chromosome 17 were considered to be a positive sign
for c-erbB2 gene amplification.
Statistics and ethics
The mean values in continuous variables are given as
mean ± standard deviation. Pearson’s chi-square test or
Fisher’s exact test were used for measuring statistical
differences in categorical variables, and all statistical
tests were two-sided. Kaplan-Meier method was
accessed for survival analysis, and the generalized Wil-
coxon test was used for estimating the difference of sur-
vival among subtypes. A Cox proportional hazard model
was used for evaluating risk factors for distant recur-
rence-free survival and overall survival. A P < 0.05 was
considered to be a statistically significant level. All tests
were two sided. Statistical analyses were performed with
SPSS 15.0 (SPSS, Chicago, IL). The present study was
approved by the Institutional Review Board of the Seoul
St. Mary’s Hospital, the Catholic University of Korea.
Results
Mean age of the patients was 48.7 years. Median follow-
up time was 93 months (range 0-164 months). The
most common subtype in the patients was luminal-A
(175/313, 55.9%), followed by TNBC (62/313, 19.8%),
HER2-enriched (42/313, 13.4%), and luminal-HER2 (34/
313, 10.9%). Clinicopathological characteristics are
shown in Table 1. All variables showed no significant
difference among subtypes (P > 0.05).
Distant recurrence occurred in 70 patients. Bone was
the most common site of the first distant recurrence
(30/70, 35.7%). Extra-bone metastasis had been shown
in 25 patients, and brain metastasis was four patients.
Multiple distant metastasis as the first distant recurrence
was occurred in 11 patients: Eight patients with bone
and extra-bone metastasis excluding brain metastasis
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and four patients with brain with other metastasis were
presented.
The difference of the site of the first distant recur-
rence was significantly different among subtypes (P =
0.04, Table 2). While bone metastasis was the most
common type of the distant recurrence in luminal-A
and luminal-HER2 types (54.3% and 50.0%, respectively),
extra-bone metastasis excluding brain metastasis was
more frequently observed than bone metastasis in
HER2-enriched and TNBC types. Brain metastasis alone
developed in 16.7% of luminal-HER2 and 12.5% of
TNBC types.
Cumulative frequency data of distant metastasis site
during follow-up are shown in Table 3. Brain metastasis
developed in luminal-A, luminal-HER2, and TNBC
types, but not in HER2-enriched type, and was
statistically significant (P = 0.03). However, cumulative
frequency of bone, lung, pleural or peritoneal, liver, and
the other sites was not significantly different among
subtypes (P > 0.05).
Figure 1 illustrates DRFS and OS according to the
subtypes. No significant difference in DRFS was present
among the subtypes. However, OS showed differences in
survival among subtypes (P = 0.02). When multivariate
analysis for DRFS was performed (Table 4), tumor size,
lymph node status, subtypes, and the site of the first
recurrence were not associated with DRFS. In multivari-
ate analysis for OS, however, HER2-enriched type,
extra-bone metastasis, and brain metastasis were signifi-
cantly related with poor OS (P < 0.05, Table 4). When
the cases were stratified by onset of distant recurrence,
the OS of early recurrence cases (distant recurrence
Table 1 Clinicopathological characteristics according to the subtypes
Luminal-A, n = 175(%) Luminal-HER2, n = 34(%) HER2-enriched, n = 41(%) TNBC, n = 62(%) P
Age 0.07
≤ 35 11(6.3) 7(20.6) 3(7.1) 6(9.7)
> 35 164(93.7) 27(79.4) 39(92.9) 56(90.3)
Menopausal state, n = 299 0.07
Premenopause 102 18 17 27
Menopause 65 16 24 30
Tumor size, n = 309 0.73
≤ 5 cm 158(90.8) 31(91.2) 35(85.4) 55(91.7)
> 5 cm 16(9.2) 3(8.8) 6(14.6) 5(8.3)
Nodal status, n = 306 0.59
Negative 95(54.9) 15(44.1) 25(59.5) 31(54.4)
Positive 78(45.1) 19(55.9) 17(40.5) 26(45.6)
Operation type 0.13
BCS 22(12.6) 1(2.9) 2(4.8) 3(4.8)
Mastectomy 153(87.4) 33(97.1) 40(95.2) 59(95.2)
Lymphovascular invasion 0.42
Absent 90(51.4) 17(50.0) 23(54.8) 25(40.3)
Present 85(48.6) 17(50.0) 19(45.2) 37(59.7)
Systemic therapy, n = 311 0.26
None 3(1.7) 1(2.9) 0 2(3.3)
Done 172(98.3) 33(97.1) 41(100) 59(96.7)
Radiation, n = 309 0.36
None 148(85.1) 30(90.9) 37(88.1) 56(93.3)
Done 26(14.9) 3(9.1) 5(11.9) 4(6.7)
Overall survival events 31(17.7) 11(32.4) 13(31.0) 15(24.2) 0.11
Table 2 Pattern of the first distant recurrence site
Luminal-A(%) Luminal-HER2(%) HER2-enriched(%) TNBC(%) P
Bone 19(54.3) 6(50.0) 3(42.9) 2(12.5) 0.04
Extra-bone (excluding Brain) 9(25.7) 3(25.0) 4(57.1) 9(56.3)
Bone + extra-bone (excluding Brain) 4(11.4) 1(8.3) 0 3(18.8)
Brain 0 2(16.7) 0 2(12.5)
Brain + other metastasis 3(8.6) 0 0 0
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within 24 months after surgery) were not significantly
different by subtypes, while the OS of late recurrence
cases (distant recurrence after 24 months after surgery)
were significantly different by subtypes (P < 0.001)
(Figure 2).
Discussion
Since molecular subtypes of breast cancer have been
identified [4], many studies have explored the clinical
value of the molecular subtypes of breast cancer [5,8,9].
However, most studies have focused on clinicopathologi-
cal features, different risks of recurrence, and response
to systemic therapies according to the molecular sub-
types [9-11], and only a few studies have described dif-
ferent distant metastatic patterns according to molecular
subtypes [7,12]. A retrospective study analyzed a large
dataset and demonstrated a distinct pattern of meta-
static behavior of the molecular subtypes using a vali-
dated six-marker immunohistochemical panel applied to
tissue microarrays, even though the clinicopathological
features of the molecular subtypes that might influence
the pattern of distant recurrence differed among the
molecular subtypes [7]. The current study demonstrated
that different patterns of distant recurrence among the
subtypes with well-balanced clinicopathologic features
remained in terms of the first distant recurrence site,
frequency of brain metastasis, overall survival, and onset
of distant recurrence.
Distant recurrence-free survival was not different
among the subtypes, yet OS showed significant differ-
ences. Generally, patients with bone metastasis show
better survival than those with visceral metastasis [13],
and bone metastasis is more common in luminal types
than the other subtypes [7,12]. Therefore, the discor-
dance between DRFS and OS might derive from the dif-
ference of the sites of the distant recurrence of the four
subtypes.
Previous studies have reported a significant difference
in the onset of recurrence according to hormone recep-
tor status and hormonal therapy [14-17]; usually low-ER
positive or ER negative tumors are associated with early
recurrence [14,17]. In the current study, early distant
recurrence was not related to the molecular subtypes.
This was not concordant with the previous studies that
Table 3 Cumulative frequency of distant metastasis sites during follow-up
Luminal-A(%) Luminal-HER2(%) HER2-enriched(%) TNBC(%) P
Bone 24(13.7) 7(20.6) 4(9.5) 6(9.7) 0.42
Lung 11(6.3) 4(11.8) 1(2.4) 7(11.3) 0.23
Pleural/peritoneal 2(1.1) 0 0 0 1.0
Liver 7(4.0) 1(2.9) 5(11.9) 5(8.1) 0.16
Brain 4(2.3) 3(8.8) 0 5(8.1) 0.03
Other 1(0.6) 0 0 2(3.2) 0.24
Figure 1 Distant recurrence-free survival (A) and overall survival (B) according to molecular subtypes.
Park et al. World Journal of Surgical Oncology 2012, 10:4
http://www.wjso.com/content/10/1/4
Page 4 of 7
demonstrated TNBC- or ER-negative tumors are related
with early relapse [7,14,17]. However, interpretation of
this discordance needs to be done cautiously, because
the definition of early relapse and study design of the
previous studies are so heterogenous that directly com-
parison with each study cannot be made. The patients
with HER2 overexpression, luminal-HER2 and HER2-
enriched subtypes, with late distant recurrence were
associated with poorer survival than luminal-A and
TNBC; these findings may be associated with lack of
trastzumab therapy because this therapy was approved
and covered by the government and national insurance
system in Korea in the mid-2000s. In addition, race may
influence the discordance because disparities in breast
cancer prognostic factors by race may exist [18]. Regard-
ing the study population of the current study, the
ethnicity is also considered to interpret the discordance
from previous studies which were mainly from Western
countries [7,14]. A previous Taiwanese study mentioned
that TNBC in Taiwan may have different prognostic fac-
tors and features compared with Western countries,
possibly due to genetic heterogeneity [19]. In addition, a
previous study reported gene expression profile differ-
ences in breast cancer between African American and
non-African American women supporting that genetic
heterogeneity in the tumor microenvironment from dif-
ferent ethnicity may account for the difference in the
site of distant metastasis [20]. There might be an ethnic
factor related to metastatic patterns of breast cancer,
and further investigations are needed.
The pattern of distant recurrence in TNBC has been
well-investigated because of its distinct pattern [21-24].
Table 4 Multivariate analysis for distant recurrence-free survival (DRFS) and overall survival (OS)
DRFS OS
P HR 95.0% CI P HR 95.0% CI
Subtype
Luminal-A Ref. Ref.
Luminal-HER2 0.57 1.26 0.55-2.85 0.64 1.23 0.50-2.98
HER2-enriched 0.39 1.52 0.57-4.03 0.01 3.76 1.35-10.49
TNBC 0.69 1.15 0.56-2.36 0.71 1.16 0.50-2.66
Metastatic site
Bone Ref. Ref.
Extra-bone (excluding brain) 0.67 0.87 0.46-1.64 0.05 2.05 0.99-4.23
Bone + extra-bone (excluding brain) 0.15 0.53 0.21-1.28 0.75 1.18 0.40-3.45
Brain 0.24 2.63 0.51-13.57 0.03 3.92 1.11-13.80
Brain + extra-brain 0.62 1.38 0.37-5.08 0.51 1.71 0.34-8.57
Tumor size (< 5 cm vs. ≥ 5 cm) 0.96 0.98 0.42-2.28 0.71 0.82 0.30-2.25
Nodal status (N0 vs. ≥ N1) 0.97 0.99 0.54-1.81 0.87 1.06 0.49-2.25
Age (continuous variable) 0.22 1.02 0.98-1.05 0.90 0.99 0.96-1.03
Figure 2 Overall survival according to the onset of distant recurrence. Overall survival according to the onset of distant recurrence (A)
Overall survival (OS) between early and late recurrence cases (distant recurrence < 24 months and ≥ 24 months after surgery). (B) OS according
to the subtypes in patients with early distant recurrence (distant recurrence within 24 months after surgery). (C) OS according to the subtypes in
patients with late distant recurrence (distant recurrence ≥ 24 months after surgery).
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Brain metastasis is common in TNBC; previous studies
have reported an incidence of brain metastasis of 6%-
10% [7,12,23,24], similar to our results. These previous
studies also reported about an incidence of CNB
metastasis of about 10% among patients with early
stage HER2 positive tumor, which is concordant with
the 8.8% of brain metastasis in luminal-HER2 type, but
higher than the rate found for the HER2-enriched
type. The incidence of brain metastasis in patients
with HER2-positive metastatic tumor who received
trastuzumab has been reported to be 25%-34% [25,26].
The frequency of brain metastasis in patients with
HER2-positive metastatic tumor, luminal-HER2 and
HER2-enriched metastatic tumor, in the current study
(3/19, 15.7%) is lower, and is perhaps associated with
the lack of trastuzumab therapy. In the absence of
trastuzumab therapy for HER2-positive breast cancer
patients, other visceral metastases may develop and
earlier failure in other visceral organ may cause death
before the development of brain metastasis.
The limitations of the study are the small number of
the cases, its retrospective design, and the fact that sys-
temic therapy guidelines during the era of this cohort
are not representative of current practice guidelines. A
major strength of the study is that the well-balanced
clinicopathological features in this cohort allowed more
clear demonstration of the metastatic pattern according
to molecular subtypes. In addition, a full review of the
medical records permitted a check of the detailed docu-
mented metastatic sites and date of up to the first three
distant recurrences, providing a more apparent pattern
of cumulative frequency of distant metastasis sites as
well as onset of distant metastasis.
Conclusions
In conclusion, this study demonstrates that the pattern
of distant metastasis is different among the molecular
subtypes as defined by ER, PR, and HER2 status, and
may contribute to an understanding of molecular sub-
type that will allow for tailored therapy for metastatic
breast cancer.
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